These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20688442)

  • 1. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
    Stevenson JC; Durand G; Kahler E; Pertyński T
    Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D; Conradt C; Jesinger D; Bakowski M
    Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
    Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate.
    Bergeron C; Nogales FF; Rechberger T; Tatarchjuk T; Zipfel L
    Maturitas; 2010 Jun; 66(2):201-5. PubMed ID: 20378287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
    Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
    Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen--no matter how delivered--relieves postmenopausal vasomotor symptoms.
    Bachmann G
    Menopause; 2003; 10(6):494-6. PubMed ID: 14627856
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile.
    Quereux C; Pornel B; Bergeron C; Ferenczy A
    Maturitas; 2006 Feb; 53(3):299-305. PubMed ID: 16043317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study.
    Liu J; Allgood A; Derogatis LR; Swanson S; O'Mahony M; Nedoss B; Soper H; Zbella E; Prokofieva SV; Zipfel L; Guo CY
    Fertil Steril; 2011 Jan; 95(1):366-8. PubMed ID: 20850731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of two oral doses of 17beta-estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double-blind placebo-controlled study.
    Rousseau A; Robert A; Gerotziafas G; Torchin D; Zannad F; Lacut K; Libersa C; Dasque E; Démolis JL; Elalamy I; Simon T
    Fundam Clin Pharmacol; 2010 Apr; 24(2):239-45. PubMed ID: 19719551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.
    Tuomikoski P; Haapalahti P; Sarna S; Ylikorkala O; Mikkola TS
    Ann Med; 2010 Jul; 42(5):334-43. PubMed ID: 20429800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
    Stevenson JC; Rioux JE; Komer L; Gelfand M
    Climacteric; 2005 Dec; 8(4):352-9. PubMed ID: 16390770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
    Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
    Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
    Archer DF;
    Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.